KB-1656

Datopotamab

49381

Home » Datopotamab

Background of Datopotamab

Trop2 is a type I cell surface glycoprotein, which is limited in normal tissues but highly expressed in human tumor tissues. Overexpression of TROP2 can promote the growth, proliferation and metastasis of tumor cells. This differentiated expression of TROP2 protein makes it a new target for researchers to develop antibody-coupled drugs. Dato-DXd bound specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and DXd release, which induced DNA damage and Apoptosis in TROP2-expressing tumor cells in vitro.

Specifications

Catalog Number	KB-1656
Antibody Name	Datopotamab
Isotype	Human IgG1, kappa
FC Muations	WT
Target	TROP2
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011 Jul;59(7):701-10.
Okajima D, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Dec;20(12):2329-2340.